Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pia Lundman

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Atherosclerosis|June 16, 2015
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysisBjörn W Karlson, Michael K Palmer, Stephen J Nicholls, et al.
Cardiovascular Diabetology|November 25, 2021
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failureViktor Lind, Niklas Hammar, Pia Lundman, et al.
European Journal of Preventive Cardiology|August 7, 2015
Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysisBjörn W Karlson, Michael K Palmer, Stephen J Nicholls, et al.
Atherosclerosis|March 21, 2013
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGERBjörn W Karlson, Stephen J Nicholls, Pia Lundman, et al.
European Journal of Preventive Cardiology|May 7, 2013
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER databaseMike K Palmer, Stephen J Nicholls, Pia Lundman, et al.
Cytokine|July 26, 2024
Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarctionSofia Cederström, Tomas Jernberg, Ann Samnegård, et al.
American Heart Journal|June 24, 2010
Cockcroft-Gault is better than the Modification of Diet in Renal Disease study formula at predicting outcome after a myocardial infarction: data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)Karolina Szummer, Pia Lundman, Stefan H Jacobson, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 4, 2025
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort studyAli Yari, Carl-Emil Lim, Emil Hagström, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGERBjörn W Karlson, Olov Wiklund, Michael K Palmer, et al.
Heart (British Cardiac Society)|February 6, 2025
Dysglycaemia and incident aortic stenosis: a cohort studyViktor Lind, Pia Lundman, Leif Friberg, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Atherosclerosis|June 16, 2015
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysisBjörn W Karlson, Michael K Palmer, Stephen J Nicholls, et al.
Cardiovascular Diabetology|November 25, 2021
Impaired fasting glucose: a risk factor for atrial fibrillation and heart failureViktor Lind, Niklas Hammar, Pia Lundman, et al.
European Journal of Preventive Cardiology|August 7, 2015
Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysisBjörn W Karlson, Michael K Palmer, Stephen J Nicholls, et al.
Atherosclerosis|March 21, 2013
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGERBjörn W Karlson, Stephen J Nicholls, Pia Lundman, et al.
European Journal of Preventive Cardiology|May 7, 2013
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER databaseMike K Palmer, Stephen J Nicholls, Pia Lundman, et al.
Cytokine|July 26, 2024
Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarctionSofia Cederström, Tomas Jernberg, Ann Samnegård, et al.
American Heart Journal|June 24, 2010
Cockcroft-Gault is better than the Modification of Diet in Renal Disease study formula at predicting outcome after a myocardial infarction: data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)Karolina Szummer, Pia Lundman, Stefan H Jacobson, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 4, 2025
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort studyAli Yari, Carl-Emil Lim, Emil Hagström, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGERBjörn W Karlson, Olov Wiklund, Michael K Palmer, et al.
Heart (British Cardiac Society)|February 6, 2025
Dysglycaemia and incident aortic stenosis: a cohort studyViktor Lind, Pia Lundman, Leif Friberg, et al.
Pageof 7